Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICI NOLVADEX PREVENTION STUDY FOR WOMEN AT RISK

Executive Summary

ICI NOLVADEX PREVENTION STUDY FOR WOMEN AT RISK of breast cancer should be considered, National Cancer Institute Director Samuel Broder, MD, suggested at a Jan. 26 meeting of the NCI Cancer Prevention and Control Division's Board of Scientific Counselors. Broder suggested the board "discuss . . . a randomized, placebo-controlled study following tamoxifen . . . in a certain population of women who are at risk of breast cancer." He added that "there are pros and cons" for such a study. A nonsteroidal antiestrogenic hormone product, Nolvadex is indicated for treatment of metastatic breast cancer in postmenopausal women but not for prophylactic use. Last May NCI mailed to 12,000 physicians study results on the positive effects of tamoxifen as an adjuvant therapy in stage one, node negative breast cancer patients. "The ball is in your court," Broder told the board. "I could foresee by way of long speculation that we might be able to identify someone who does not have cancer but who does have some abnormality that we might be able to correct in advance." However, he cautioned that the question of safety regarding such a trial "is extremely important."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel